Amgen Presents New Data at ASCO

Amgen presented new data from the company’s oncology portfolio on both approved and investigational cancer therapies at the 44th Annual American Society of Clinical Oncology (ASCO) Meeting in Chicago:

• Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline
• Interim Phase 2 Results of Open-label Clinical Trial of Denosumab in Giant Cell Tumor of Bone Demonstrated 87 Percent Response Rate
• Amgen Reports Positive Data at ASCO from Three Studies of Denosumab in Cancer Patients
• Updated Data from Ongoing Phase 3 Trials Support the Continued Study of Vectibix® (Panitumumab) in Combination with Standard Chemotherapy